TSH Stimulation Methods Show Comparable Outcomes in Radioiodine-Avid Metastatic Differentiated Thyroid Cancer

Background

Differentiated thyroid cancer (DTC) is usually highly treatable, but a subset of patients develops distant metastases, meaning the cancer has spread beyond the neck to organs such as the lungs or bones. When these metastases still take up radioactive iodine, radioiodine therapy (RAIT) can be an important treatment option. The goal of RAIT is to deliver targeted radiation to cancer cells that retain the ability to absorb iodine.

For RAIT to work well, cancer cells need to express more of the sodium-iodide symporter, the protein that helps pull iodine into thyroid cells. This can be stimulated in two main ways: recombinant human TSH (rhTSH), a medication that raises TSH without requiring the patient to become hypothyroid, or thyroid hormone withdrawal (THW), which involves stopping thyroid hormone replacement and allowing the body’s own TSH level to rise naturally. Both methods are used in practice, but their relative impact on long-term outcomes in metastatic, radioiodine-avid DTC has been less certain.

This study examined whether the way patients were prepared for RAIT influenced radiologic response, biochemical response, time to progression, and overall survival.

Study Design and Patients

This was a single-center retrospective observational study of 189 consecutive eligible patients who started RAIT between 2005 and 2015. The study period was long enough to allow meaningful follow-up and assessment of long-term outcomes. All included patients had distant metastatic DTC that was avid for radioiodine, meaning their metastases still showed uptake of radioactive iodine and were therefore potentially treatable with RAIT.

Patients were divided into two groups based on how TSH stimulation was achieved across their treatment course:
1. rhTSH only: all RAIT activities were prepared using recombinant human TSH.
2. Mixed stimulation: at least one RAIT activity was prepared using thyroid hormone withdrawal, even if other treatments used rhTSH.

A small number of patients who were treated only with THW were excluded because the sample size was too small for reliable statistical analysis.

The researchers then compared outcomes between groups, both before and after adjusting for differences in baseline characteristics. They also used propensity score matching, a statistical method that helps make two groups more comparable by balancing important clinical factors.

What Was Measured

The main outcomes included:
– Radiologic response: how tumors looked on imaging after treatment
– Biochemical response: changes in blood markers, especially thyroglobulin, which can reflect thyroid cancer activity
– Time to progression (TTP): how long it took before the cancer worsened
– Overall survival (OS): how long patients lived after treatment initiation

Radiologic responses were categorized as complete response, partial response, stable disease, or progressive disease.

Key Findings

The median follow-up was 123 months, with a wide range from 3 to 182 months, allowing the investigators to assess both medium- and long-term outcomes.

Overall, the most common best radiologic outcome was stable disease, seen in 49% of patients. Complete response occurred in 23%, partial response in 18%, and progressive disease in 10%. Importantly, these response patterns did not differ significantly between the rhTSH-only group and the mixed-stimulation group.

When the researchers looked at the raw, unadjusted data, the mixed-stimulation group appeared to do better, with longer time to progression and better overall survival. Specifically, median TTP was 141 months in the mixed group versus 42 months in the rhTSH-only group, and median OS was 116 months versus 68 months, respectively. These differences initially suggested a possible advantage for mixed preparation.

However, once the investigators adjusted for other important clinical factors, the stimulation method itself was no longer independently associated with either TTP or OS. In other words, the apparent difference in survival outcomes was explained by differences in patient and disease characteristics rather than by the preparation method.

The strongest independent predictors of outcome were metastatic burden, especially the presence of macrometastases, and age at the time of DTC diagnosis. These factors were more important than whether patients received rhTSH only or mixed rhTSH/THW preparation.

The propensity score-matched analysis supported the same conclusion: after balancing the groups more fairly, there were no significant differences in time to progression or overall survival between stimulation strategies.

Clinical Interpretation

This study suggests that in patients with radioiodine-avid metastatic differentiated thyroid cancer, rhTSH preparation and mixed rhTSH/THW preparation lead to comparable adjusted outcomes. The choice of stimulation method does not appear to change the overall oncologic effectiveness of treatment once disease burden and age are taken into account.

That finding is clinically important because rhTSH offers practical advantages for many patients. It avoids the symptoms of hypothyroidism that can occur with hormone withdrawal, such as fatigue, weight gain, cognitive slowing, constipation, and reduced quality of life. It may also be preferable for patients in whom hypothyroidism could be risky, such as those with serious comorbidities.

At the same time, THW remains a valid and widely used option, especially in settings where cost, access, treatment logistics, or institutional practice favor it. This study supports individualized decision-making rather than assuming one method is universally superior.

What the Results Mean for Patients

For patients and families, the practical message is reassuring: if a patient has metastatic thyroid cancer that still absorbs iodine, the way the body is prepared for radioactive iodine treatment may not greatly affect long-term cancer control. More important factors include how extensive the metastases are and the patient’s overall clinical profile.

This can help patients and clinicians focus on the aspects of care that truly drive outcomes, while choosing the stimulation approach that best fits the patient’s health status, comfort, and treatment preferences.

Study Strengths and Limitations

A major strength of this study is the long follow-up period, which provides a more reliable view of long-term outcomes than short-term studies. Another strength is the use of multivariable analysis and propensity score matching, both of which help reduce bias in retrospective research.

Still, the study has limitations typical of retrospective single-center research. Treatment decisions were not randomized, so unmeasured differences between groups may have influenced the results. The number of patients treated exclusively with THW was too small to analyze separately. Also, because the study was conducted at one center, the findings may not fully generalize to all institutions or patient populations.

In addition, RAIT outcomes in metastatic thyroid cancer can be influenced by many variables, including lesion size, iodine avidity, prior treatments, and cumulative radioiodine dose. Not every one of these factors can be perfectly captured in retrospective data.

Bottom Line

In radioiodine-avid metastatic differentiated thyroid cancer, rhTSH-only preparation and mixed rhTSH/thyroid hormone withdrawal preparation are associated with similar adjusted treatment outcomes. Prognosis is driven mainly by metastatic burden and age at diagnosis, not by the stimulation method itself.

This supports a personalized approach to RAIT preparation, where the choice between rhTSH and THW should be guided by medical condition, practical considerations, and patient preference rather than expectations of a major difference in anticancer efficacy.